Creating a new imaging tool to visualize brain receptors related to PTSD

Development and translation of a novel radiotracer to image alpha-1 adrenoceptors using positron emission tomography for use in imaging posttraumatic stress disorder

NIH-funded research VA Puget Sound Healthcare System · NIH-10928070

This study is testing a new imaging tool that helps doctors see specific brain receptors linked to PTSD, which could lead to better treatment options for people with this condition.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionVA Puget Sound Healthcare System NIH-funded
Lab location1 site (Seattle, United States)
Project IDNIH-10928070 on NIH RePORTER

What this research studies

This research focuses on developing a novel radiotracer that can be used with positron emission tomography (PET) to visualize alpha-1 adrenoceptors in the brain, which are believed to play a significant role in posttraumatic stress disorder (PTSD). By improving our ability to image these receptors, the research aims to better understand the noradrenergic activity associated with PTSD and identify which patients may respond to treatments like prazosin. The approach involves advanced imaging techniques that are non-invasive and could lead to more personalized treatment options for individuals suffering from PTSD. This could ultimately help in tailoring therapies based on individual brain chemistry and receptor activity.

Who could benefit from this research

Good fit: Ideal candidates for this research are Veterans and Servicemembers diagnosed with PTSD who may benefit from targeted therapies.

Not a fit: Patients without a diagnosis of PTSD or those who do not have access to imaging facilities may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective and personalized treatments for PTSD, improving outcomes for patients.

How similar studies have performed: While there have been challenges in developing effective imaging tools for alpha-1 adrenoceptors, advancements in PET imaging have shown promise in other neuropsychiatric disorders, indicating potential for success in this area.

Where this research is happening

Seattle, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.